Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?

被引：17

作者：

Arico, Eleonora ^{[1
]}

Bracci, Laura ^{[2
]}

Castiello, Luciano ^{[1
]}

Gessani, Sandra ^{[3
]}

Belardelli, Filippo ^{[4
]}

机构：

[1] Ist Super Sanita, Core Facil, FaBioCell, Rome, Italy

[2] Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy

[3] Ist Super Sanita, Ctr Gender Specif Med, Rome, Italy

[4] CNR, Inst Translat Pharmacol, Via Fosso del Cavaliere 100, Rome, Italy

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2020年 / 54卷

关键词：

Type I Interferons; COVID-19; SARS-CoV-2; Coronavirus; Mucosal treatments; Immunomodulation; Antiviral therapy; Antiviral Immune Response; Beta Interferon; PROTECTIVE IMMUNE-RESPONSE; SARS-CORONAVIRUS; NERVOUS-SYSTEM; CELLS; ADJUVANT; VIRUS; BETA; MICE; IFN; COMBINATION;

D O I：

10.1016/j.cytogfr.2020.07.010

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Coronavirus disease 2019 (COVID-19) first emerged in late 2019 in China. At the time of writing, its causative agent SARS-CoV-2 has spread worldwide infecting over 9 million individuals and causing more than 460,000 deaths. In the absence of vaccines, we are facing the dramatic challenge of controlling COVID-19 pandemic. Among currently available drugs, type I Interferons (IFN-I) - mainly IFN-alpha and beta -represent ideal candidates given their direct and immune-mediated antiviral effects and the long record of clinical use. However, the best modalities of using these cytokines in SARS-CoV-2 infected patients is a matter of debate. Here, we discuss how we can exploit the current knowledge on IFN-I system to tailor the most promising dosing, timing and route of administration of IFN-I to the disease stage, with the final aim of making these cytokines a valuable therapeutic strategy in today's fight against COVID-19 pandemic.

引用

页码：43 / 50

页数：8

共 64 条

[1] Dysregulation of type I interferon responses in COVID-19 [J].

Acharya, Dhiraj ;

Liu, GuanQun ;

Gack, Michaela U. .

NATURE REVIEWS IMMUNOLOGY, 2020, 20 (07) :397-398

[2] Pathogen recognition and innate immunity [J].

Akira, S ;

Uematsu, S ;

Takeuchi, O .

CELL, 2006, 124 (04) :783-801

[3] Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use [J].

Antonelli, Guido ;

Scagnolari, Carolina ;

Moschella, Federica ;

Proietti, Enrico .

CYTOKINE & GROWTH FACTOR REVIEWS, 2015, 26 (02) :121-131

[4] Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial [J].

Arabi, Yaseen M. ;

Asiri, Ayed Y. ;

Assiri, Abdullah M. ;

Aziz Jokhdar, Hani A. ;

Alothman, Adel ;

Balkhy, Hanan H. ;

AlJohani, Sameera ;

Al Harbi, Shmeylan ;

Kojan, Suleiman ;

Al Jeraisy, Majed ;

Deeb, Ahmad M. ;

Memish, Ziad A. ;

Ghazal, Sameeh ;

Al Faraj, Sarah ;

Al-Hameed, Fahad ;

AlSaedi, Asim ;

Mandourah, Yasser ;

Al Mekhlafi, Ghaleb A. ;

Sherbeeni, Nisreen Murad ;

Elzein, Fatehi Elnour ;

Almotairi, Abdullah ;

Al Bshabshe, Ali ;

Kharaba, Ayman ;

Jose, Jesna ;

Al Harthy, Abdulrahman ;

Al Sulaiman, Mohammed ;

Mady, Ahmed ;

Fowler, Robert A. ;

Hayden, Frederick G. ;

Al-Dawood, Abdulaziz ;

Abdelzaher, Mohamed ;

Bajhmom, Wail ;

Hussein, Mohamed A. .

TRIALS, 2020, 21 (01)

[5] Type I Interferons and Cancer: An Evolving Story Demanding Novel Clinical Applications [J].

Arico, Eleonora ;

Castiello, Luciano ;

Capone, Imerio ;

Gabriele, Lucia ;

Belardelli, Filippo .

CANCERS, 2019, 11 (12)

[6] MHV-68 producing mIFNα1 is severely attenuated in vivo and effectively protects mice against challenge with wt MHV-68 [J].

Arico, Eleonora ;

Monque, Domenica M. ;

D'Agostino, Giuseppina ;

Moschella, Federica ;

Venditti, Massimo ;

Kalinke, Ulrich ;

Allen, Deborah J. ;

Nash, Anthony A. ;

Belardelli, Filippo ;

Ferrantini, Maria .

VACCINE, 2011, 29 (23) :3935-3944

[7] Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility [J].

Arons, M. M. ;

Hatfield, K. M. ;

Reddy, S. C. ;

Kimball, A. ;

James, A. ;

Jacobs, J. R. ;

Taylor, J. ;

Spicer, K. ;

Bardossy, A. C. ;

Oakley, L. P. ;

Tanwar, S. ;

Dyal, J. W. ;

Harney, J. ;

Chisty, Z. ;

Bell, J. M. ;

Methner, M. ;

Paul, P. ;

Carlson, C. M. ;

McLaughlin, H. P. ;

Thornburg, N. ;

Tong, S. ;

Tamin, A. ;

Tao, Y. ;

Uehara, A. ;

Harcourt, J. ;

Clark, S. ;

Brostrom-Smith, C. ;

Page, L. C. ;

Kay, M. ;

Lewis, J. ;

Montgomery, P. ;

Stone, N. D. ;

Clark, T. A. ;

Honein, M. A. ;

Duchin, J. S. ;

Jernigan, J. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (22) :2081-2090

[8] Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year [J].

Bennett, Alayne L. ;

Smith, David W. ;

Cummins, Martin J. ;

Jacoby, Peter A. ;

Cummins, Joseph M. ;

Beilharz, Manfred W. .

INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2013, 7 (05) :854-862

[9] Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 [J].

Blanco-Melo, Daniel ;

Nilsson-Payant, Benjamin E. ;

Liu, Wen-Chun ;

Uhl, Skyler ;

Hoagland, Daisy ;

Moller, Rasmus ;

Jordan, Tristan X. ;

Oishi, Kohei ;

Panis, Maryline ;

Sachs, David ;

Wang, Taia T. ;

Schwartz, Robert E. ;

Lim, Jean K. ;

Albrecht, Randy A. ;

tenOever, Benjamin R. .

CELL, 2020, 181 (05) :1036-+

[10] ABSORPTION OF CYTOKINES VIA OROPHARYNGEAL-ASSOCIATED LYMPHOID-TISSUES - DOES AN UNORTHODOX ROUTE IMPROVE THE THERAPEUTIC INDEX OF INTERFERON [J].

BOCCI, V .

CLINICAL PHARMACOKINETICS, 1991, 21 (06) :411-417

← 1 2 3 4 5 6 7 →